Selective progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human endometrium. by Whitaker, L.H.R. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selective progesterone receptor modulator (SPRM) ulipristal
acetate (UPA) and its effects on the human endometrium.
Citation for published version:
Whitaker, L, Murray, A, Matthews, R, Shaw, G, Williams, A, Saunders, P & Critchley, H 2017, 'Selective
progesterone receptor modulator (SPRM) ulipristal acetate (UPA) and its effects on the human
endometrium.', Human Reproduction, vol. 32, no. 3, pp. 531-543. https://doi.org/10.1093/humrep/dew359
Digital Object Identifier (DOI):
10.1093/humrep/dew359
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Human Reproduction
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
Human Reproduction, pp. 1–13, 2017
doi:10.1093/humrep/dew359
ORIGINAL ARTICLE Gynaecology
Selective progesterone receptor
modulator (SPRM) ulipristal acetate
(UPA) and its effects on the human
endometrium
L.H.R.Whitaker1,†, A.A. Murray1,†, R. Matthews1, G. Shaw1,
A.R.W.Williams2, P.T.K. Saunders3, and H.O.D. Critchley1,*
1MRC Centre for Reproductive Health, The University of Edinburgh, The Queen’s Medical Research Institute, 47 Little France Crescent,
Edinburgh EH16 4TJ, UK 2Division of Pathology, The University of Edinburgh, The Royal Infirmary of Edinburgh, 51 Little France Crescent,
Edinburgh EH16 4SA, UK 3MRC Centre for Inflammation Research, The University of Edinburgh, The Queen’s Medical Research Institute,
47 Little France Crescent, Edinburgh EH16 4TJ, UK
*Correspondence address. MRC Centre for Reproductive Health, The University of Edinburgh, The Queen’s Medical Research Institute,
Edinburgh, UK. Tel: 0131 242 6858; E-mail: hilary.critchley@ed.ac.uk
Submitted on September 24, 2016; resubmitted on November 30, 2016; accepted on January 4, 2017
STUDY QUESTION: What is the impact of administration of the selective progesterone receptor modulator (SPRM), ulipristal acetate
(UPA) on the endometrium of women with fibroids?
SUMMARY ANSWER: UPA administration altered expression of sex-steroid receptors and progesterone-regulated genes and was asso-
ciated with low levels of glandular and stromal cell proliferation.
WHAT IS KNOWN ALREADY: Administration of all SPRM class members results in PAEC (progesterone receptor modulator associated
endometrial changes). Data on the impact of the SPRM UPA administration on endometrial sex-steroid receptor expression, progesterone
(P)-regulated genes and cell proliferation are currently lacking.
STUDY DESIGN SIZE, DURATION: Observational study with histological and molecular analyses to delineate impact of treatment with
UPA on endometrium. Endometrial samples (n = 9) were collected at hysterectomy from women aged 39 to 49 with uterine fibroids treated
with UPA (oral 5 mg daily) for 9–12 weeks. Control proliferative (n = 9) and secretory (n = 9) endometrium from women aged 38–52 with
fibroids were derived from institutional tissue archives.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Study setting was a University Research Institute. Endometrial biopsies were
collected with institutional ethical approval and written informed consent. Concentrations of mRNAs encoded by steroid receptors,
P-regulated genes and factors in decidualised endometrium were quantified with qRT-PCR. Immunohistochemistry was employed for local-
ization of progesterone (PR, PRB), androgen (AR), estrogen (ERα) receptors and expression of FOXO1, HAND2, HOXA10, PTEN homo-
logue. Endometrial glandular and stromal cell proliferation was objectively quantified using Ki67.
MAIN RESULTS AND THE ROLE OF CHANCE: UPA induced morphological changes in endometrial tissue consistent with PAEC.
A striking change in expression patterns of PR and AR was detected compared with either proliferative or secretory phase samples. There
were significant changes in pattern of expression of mRNAs encoded by IGFBP-1, FOXO1, IL-15, HAND2, IHH and HOXA10 compared with
secretory phase samples consistent with low agonist activity in endometrium. Expression of mRNA encoded by FOXM1, a transcription factor
implicated in cell cycle progression, was low in UPA-treated samples. Cell proliferation (Ki67 positive nuclei) was lower in samples from
women treated with UPA compared with those in the proliferative phase.
LARGE SCALE DATA: N/A.
†The authors consider that the first two authors should be regarded as joint First Authors.
© The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
LIMITATIONS REASONS FOR CAUTION: A small number of well-characterized patients were studied in-depth. The impacts on
morphology, molecular and cellular changes with SPRM, UPA administration on symptom control remains to be determined.
WIDER IMPLICATIONS OF THE FINDINGS: P plays a pivotal role in endometrial function. P-action is mediated through interaction
with the PR. These data provide support for onward development of the SPRM class of compounds as effective long-term medical therapy
for heavy menstrual bleeding.
STUDY FUNDING/COMPETING INTEREST(S): H.O.D.C. received has clinical research support for laboratory consumables and staff
from Bayer Pharma Ag and provides consultancy advice (no personal remuneration) for Bayer Pharma Ag, PregLem SA, Gedeon Richter, Vifor
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G1100356/1; MR/N022556/1); National Health Institute for Health Research (12/206/520) and TENOVUS Scotland.
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Introduction
Heavy menstrual bleeding (HMB) is a common condition affecting up to
one in four women of reproductive age (Shapley et al., 2004). This con-
dition has significant impact upon the physical, social, emotional and
material quality of life of women (NICE, 2007). In the USA, conserva-
tive estimates of annual direct and indirect costs are $1 and $12 billion,
respectively (Liu et al., 2007). In the UK, it is estimated that 1 million
women annually seek help for HMB (NICE, 2007). There are multiple
etiologies that are associated with HMB including fibroids (leiomyomas)
(Munro et al., 2011). In women with symptomatic fibroids, HMB is the
major complaint for which treatment is sought and is a leading indica-
tion of hysterectomy in pre-menopausal women (Merrill, 2008) result-
ing in sterility, an unacceptable side effect for many women. The
mechanisms responsible for the development of these benign tumours
is not fully understood but it is well established that fibroid growth is
regulated by the actions of the sex-steroids estrogen (E) and progester-
one (P) (Yin et al., 2007, 2010; Bulun, 2013).
Progesterone is a critical regulator of female reproduction and plays a
pivotal role in endometrial differentiation and its withdrawal following
demise of the corpus luteum during a non-pregnant cycle precipitates
endometrial shedding during menstruation (Maybin and Critchley,
2015). Progesterone responses are mediated through interaction of the
steroid with the progesterone receptor (PR); a ligand-activated tran-
scription factor. It has been demonstrated that two main isoforms of the
receptor (termed PR-A and PR-B) are present within the endometrium
(Patel et al., 2015). Expression and relative abundance of these isoforms
within the tissue contribute to normal uterine function and, if dysregu-
lated, uterine pathophysiology. Notably, activation of P-responsive
genes has been linked with reduced apoptosis and enhanced prolifer-
ation of fibroid cells (Yin et al., 2007, 2010).
Administration of synthetic progestins is a medical therapy cur-
rently used for managing HMB, however, these therapies often either
fail to fully resolve symptoms or are associated with unacceptable
side effects (Roberts et al., 2011). The development of a new class of
synthetic compounds the ‘selective progesterone receptor modula-
tors’ (SPRMs) exhibiting mixed agonist and antagonist activity appears
to offer a new approach to medical management of hormone dep-
endent uterine disorders such as HMB and fibroids (Wagenfeld et al.,
2016). Class members include mifepristone, asoprisnil and ulipristal
acetate (UPA).
Administration of the SPRMs mifepristone and asoprisnil has been
reported to reduce both fibroid volume and menstrual blood loss
(Wilkens et al., 2008; Engman et al., 2009). Currently the SPRM, UPA
is the only member of this class of drug licensed in Europe for short-
term treatment of fibroids prior to hysterectomy and more recently
(in Europe) for intermittent treatment of moderate to severe symp-
toms of uterine fibroids in adult women of reproductive age. In clinical
studies, utilizing a regime of repeated doses of UPA it has been shown
that median fibroid volume was reduced by 45% of women receiving
treatment and nearly 90% of patients reported a significant reduction
in menstrual bleeding (Donnez et al., 2014).
UPA administration, in common with that of other SPRMs, is associ-
ated with morphological changes of the endometrium. Characteristics of
these effects include large cystic glands, changes within the stromal comp-
artment including the fibroblasts and vasculature and are now recognized
as a distinct histological entity, termed progesterone receptor modulator
associated endometrial changes (PAEC) (Williams et al., 2012).
Studies have demonstrated that the SPRMs mifepristone and UPA
both exert anti-proliferative and pro-apoptotic effects on leiomyoma cells
in vitro (Luo et al., 2010; Yin et al., 2010), which may explain mechanisms
by which fibroid volume is reduced but there are very limited data as to
the mechanism of SPRM action within the intact endometrium.
The mechanism by which control of bleeding is achieved is unclear.
Clinical trials report bleeding control in up to 98% of women but only
around 70–74% exhibit PAEC (Donnez et al., 2012a,b; Williams et al.,
2012). Furthermore, some patients who continue to ovulate still
achieve amenorrhoea (Chabbert-Buffet et al., 2007). Hence it is essen-
tial to delineate potential endometrial causes for the mitigation of men-
strual bleeding.
In this study, we have used histological and molecular analyses to
delineate the impact of treatment with UPA for 9–12 weeks on endo-
metrial tissue focusing on expression of sex-steroid receptors, the pro-
ducts of genes known to be progesterone-regulated during the normal
cycle and the impact upon endometrial cell proliferation.
The data presented here offer evidence that UPA, a licensed SPRM
alters expression of sex-steroid receptors and PR regulated genes
without increasing endometrial cell proliferation.
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Materials andMethods
Patients and samples
After ethical approval (Research Ethics Committee 12/SS/0238; 10/S1402/
59) and written informed consent, endometrial biopsies (n = 9) were col-
lected at the time of surgery from women aged 39 to 49 years with symp-
tomatic uterine fibroids treated with UPA (oral 5 mg daily) for 9–12 weeks
(63–84 days) up to the time of hysterectomy (Table I). All subjects with one
exception described excellent control of bleeding whilst receiving UPA with
either complete amenorrhoea or only occasional spotting. Control prolifera-
tive (n = 9) and secretory (n = 9) endometrium from pre-menopausal
women aged 38–52 undergoing hysterectomy for symptomatic fibroids
were utilized from tissue archives (REC: 10/S1402/59). All control patients
were women with fibroids who reported regular menstrual cycles and no
preoperative hormone use. Median estradiol and progesterone serum levels
were 497 (range 12.5–1272) and <3 (<3–5.7) in the proliferative group and
323 (range 77.4–530) and 27.1 (14.8–45.7) in the secretory group. Age and
BMI were not significantly different from the UPA-treated group. Control
endometrial tissues were staged based on standard histological criteria
(Noyes et al., 1950), the patient’s reported last menstrual period, and circu-
lating estradiol and progesterone levels at the time of collection.
Gene expression analyses
RNA was isolated from endometrial samples using Qiagen RNAeasy mini
kit as per manufacturer’s protocol (Qiagen, UK). Quality of RNA was ana-
lyzed using the Agilent RNA 600 nano kit according to manufacturer’s
protocol (Agilent Technologies, USA). RNA integrity numbers were all
greater than 7.7. cDNA was prepared using Superscript Vilo cDNA kit
(Invitrogen, UK) using 100 ng RNA as template. Taqman RT-qPCR was
performed in triplicate reactions using primers designed using the online
Universal Probe Assay (Roche Diagnostics, USA) and synthesized by
Eurofins Genomics (Germany) (Table II) on an ABI Prism Cycler (Applied
Biosystems USA). Indian hedgehog (IHH) and phosphatase and tensin
homologue (PTEN) primers were bought as pre-validated sets (Applied
Biosystems, UK) and used according to the manufacturer’s protocol.
Relative quantification of target genes were analyzed after normalization to
the geometric mean of endogenous ATP synthase H+ transporting mito-
chondrial F1 complex, Beta polypeptide (ATPB5) and 18s and a control
sample by the comparative ΔΔCT method.
Immunohistochemistry
Tissue samples were fixed in 4% neutral buffered formalin, sectioned, pro-
cessed and stained with Haematoxylin and Eosin by standard methods. For
immunohistochemistry 5 μm sections were subjected to antigen retrieval
(Table III); non-specific activity was blocked sequentially with 3% hydrogen
peroxide and appropriate serum before overnight incubation at 4°C with
antibodies specific to: PR, PRB, androgen receptor (AR), estrogen recep-
tor alpha (ERα), FOXO1, HAND2, HOXA10, PTEN and Ki67 (Table III).
Appropriate matched IgG was applied as a negative control. Sections were
incubated with ImmPRESS™ Ig reagents (Table III); bound antibodies were
visualized using 3,3′-diaminobenzidine (Vector Laboratories, UK). Sections
were counterstained with haemotoxylin and mounted in Pertex (Cellpath
Technologies, UK). Representative images were captured using an
Olympus BX51 microscope equipped with a Nikon DSFi1 camera
(Olympus Optical Co. and Nikon Ltd, UK).
Analysis and scoring of proliferation marker
expression
Ki67 stained sections (n = 6/group) were scanned using a Zeiss Imager
A1microscope, fitted with a Prior Proscan II automatic stage (Zeiss, UK).
For each scanned image 20 random fields were automatically selected by
the programme and a 28 × 20 point grid was applied using Image Pro Plus
7.0 software. There were a total of 560 points (intersections of the grid)
per field categorized as: (i) stained (positive) stromal cells, (ii) stained
.............................................................................................................................................................................................
Table I Subject characteristics and endometrial histology.
Subject Age
(Year)
Symptoms Submucosal
component
of fibroid
Duration of
UPA (days)
Bleeding
control
Histology
A 43 HMB pain No 83 Amenorrhoea Extensive features of PAEC with widespread cystic glandular
dilatation. Occasional thick-walled vessels
B 48 HMB pain No 63 Amenorrhoea Extensive features of PAEC with widespread cystic glandular
dilatation. No abnormal vessels
C 39 HMB Yes 84 Amenorrhoea Extensive features of PAEC with widespread cystic glandular
dilatation. No abnormal vessels
D 39 HMB
pressure
Yes 76 Occasional
spotting only
Some features of PAEC with occasional dilated cystic glands with
tortuous morphology
E 49 HMB
pressure
No 77 Amenorrhoea Some features of PAEC with occasional dilated cystic glands with
tortuous morphology
F 45 HMB Yes 81 Increased
HMB
Some features of PAEC with occasional dilated cystic glands with
tortuous morphology
G 45 HMB
pressure
Yes 84 Amenorrhoea Some features of PAEC with occasional dilated cystic glands with
tortuous morphology. Several thick-walled vessels
H 47 HMB
pressure
Yes 75 Irregular
spotting
Some features of PAEC with occasional dilated cystic glands with
tortuous morphology
I 46 HMB
pressure
No 63 Amenorrhoea Minimal features of PAEC with occasional partially dilated cystic glands
UPA, ulipristal acetate; HMB, heavy menstrual bleeding; PAEC, progesterone receptor modulator associated endometrial changes.
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(positive) glandular cells, (iii) unstained (negative) stromal cells, (iv)
unstained (negative) glandular cells and (v) all other points not overlaying
any cells (e.g. empty slide space, lumen, connective tissue or blood). Points
not overlaying a cell were excluded from analysis. The proportion of tissue
in which each of the categorized cell type occupied was expressed as a
percentage of total calculated area; cell proliferation index.
Statistics
Data were analyzed using Graphpad prism software (Graphpad, USA) util-
izing non-parametric tests. Kruskal–Wallis test was used to determine dif-
ferences between sample groups. Results are presented as mean ± SEM.
P < 0.05 was considered to be statistically significant.
Results
Impact of UPA administration
on endometrial morphology
Endometrium from all women treated with UPA showed some histo-
logical features of PAEC (Table I). Individual images are illustrated in
Fig. 1. Some showed more extensive cystic glandular dilatation than
others (Fig. 1A–C); the extent of dilatation did not correlate to the
presence of submucosal fibroids, duration of treatment or control of
bleeding (Table I). No subjects exhibited histological evidence of
inflammation, hyperplasia or neoplasia.
Treatment with UPA increases
concentrations of mRNAs encoded by
sex-steroid hormone receptors
Concentrations of PR and PRB mRNAs were significantly lower in secre-
tory endometrium compared to proliferative tissue. UPA administration
was associated with significantly higher PR and PRB mRNA concentra-
tions than secretory phase endometrium but was not significantly differ-
ent to proliferative phase samples (Fig. 2A and B). Total ARmRNA levels
in UPA-treated samples were significantly increased compared to both
proliferative and secretory phase samples. AR mRNA concentrations
were not significantly different between proliferative and secretory phase
samples (Fig. 2C). Concentrations of ESR1 (ERα) mRNA in secretory
.............................................................................................................................................................................................
Table II Primers and probes for quantitative PCR.
Target gene Forward primer Reverse primer Roche probe
PR tttaagagggcaatggaagg cggattttatcaacgatgcag 11
PRB aatgggctgtaccgagaggt tctcagtccctcgctgagtt 45
AR gctgatcataggcctctctc tgccctgaaagcagtcctct 14
ESR1 aaccagtgcaccattgataaaa tcctcttcggtcttttcgtatc 68
IGFBP-1 aatggattttatcacagcagacag ggtagacgcaccagcagagt 58
FOXO1 aagggtgacagcaacagctc ttccttcattctgcacacga 11
IL-15 cagatagccagcccatacaag ggctatggcaaggggttt 46
HAND2 tcaagaagaccgacgtgaaa gttgctgctcactgtgcttt 35
HOXA10 ccttccgagagcagcaaa ttggctgcgttttcacct 61
FOXM1 actttaagcacattgccaagc cgtgcagggaaaggttgt 11
COUP TFII ccatagtcctgttcacctcaga aatctcgtcggctggttg 36
BMP2 cggactgcggtctcctaa ggaagcagcaacgctagaag 49
.............................................................................................................................................................................................
Table III Antibodies for immunohistochemistry.
Protein Supplier Reference Antibody
type
Host Dilution
(normal horse serum)
Retrieval
Buffer
ImmPRESS™
kit
PR Dako A0098 Polyclonal Rabbit 1:200 Citrate Rabbit MP-7401
PRB Cell signalling 3157S Monoclonal Rabbit 1:800 Citrate Rabbit MP-7401
AR Spring bioscientific M4070 Monoclonal Rabbit 1:200 Citrate Rabbit MP-7401
ERα Vector VP-E614 Monoclonal Mouse 1:5000 Citrate Mouse MP-7402
FOXO1 Cell signalling 2880 Monoclonal Rabbit 1:250 Citrate Rabbit MP-7401
PTEN Dako M3627 Monoclonal Mouse 1:750 Citrate Mouse MP-7402
HAND2 Santa Cruz SC9409 Polyclonal Goat 1:200 Citrate Goat MP-7405
HOXA10 Santa Cruz SC17159 Polyclonal Goat 1:200 Citrate Goat MP-7405
Ki67 NovaCastra NCL-Ki67-MM1 Monoclonal Mouse 1:500 TRIS Mouse MP-7402
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phase were significantly lower than proliferative phase and concentra-
tions in UPA-treated samples were significantly higher than secretory
phase. There was no significant different in ESR1 concentration between
proliferative phase and UPA-treated samples (Fig. 2D).
Immunoexpression of endometrial
sex-steroid receptors was altered
by UPA administration
In agreement with previous studies (Lessey et al., 1988; Wang et al.,
1998) intense immunopositive staining for PR (with antibody recognizing
both isoforms) was detected in cell nuclei in both glandular epithelial
cells and stromal fibroblasts in proliferative endometrium. Intensity was
reduced in epithelial cell nuclei in the secretory phase (Fig. 3C versus D).
UPA-treated endometrium with marked and minimal cystic glandular
dilatation (Fig. 3A and B, respectively) showed a pattern of PR immuno-
positive staining characterized by intense staining of nuclei in glandular
epithelium and weak/negligible immunoexpression in stromal fibro-
blasts. This pattern did not phenocopy either proliferative or secretory
endometrium (Fig. 3C and D). These results were mirrored by results
obtained using a PRB-specific antibody (Fig. 3E–H).
Consistent with previous findings in our group (Marshall et al.,
2011), intense immunopositive staining for AR was detected in nuclei
of stromal fibroblasts in proliferative endometrium (Fig. 3K); AR
Figure 1 Selective progesterone receptor modulator (SPRM), ulipristal acetate (UPA) modifies endometrial morphology. Haematoxylin and eosin
staining of full thickness endometrium from hysterectomy specimens of nine subjects with uterine fibroids exposed to UPA for up to 12 weeks. All spe-
cimens exhibited progesterone receptor modulator associated endometrial changes (PAEC) but with variation in the degree of cystic glandular dilata-
tion, and in overall endometrial thickness. Subjects A–C showed widespread extensive cystic dilatation that was less frequently observed in subjects
D–H. Subject I had minimal cystic change. No subjects exhibited histological evidence of inflammation, hyperplasia or neoplasia. ×4 magnification (scale
bar = 500 µm); LE, Luminal epithelium; G, Glands; S, Stroma.
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positive epithelial cells were only detected in secretory phase (Fig. 3L)
coincident with a reduction in staining intensity in stromal cells.
Immunostaining of UPA-treated endometrial sections revealed a uni-
que pattern characterized by intense immunopositive staining of cell
nuclei in both epithelial cells and stromal fibroblasts (Fig. 3I and J). The
expression profile of ERα (ESR1) protein differed between proliferative
and secretory endometrium with reduced immunoexpression
detected in secretory phase tissue in both stromal fibroblasts and glan-
dular epithelium (Fig. 3O and P). ERα immunoexpression in UPA-
treated endometrium mirrored that of proliferative endometrium but
was less intense in subjects with minimal cystic glandular dilatation
(Fig. 3M and N).
The impact of UPA administration on PR
responsive genes
As UPA is a SPRM, further investigations focused on genes known to
be regulated during the progesterone-dominated secretory phase of
the cycle and associated with decidualisation (Wetendorf and
DeMayo, 2012). In contrast to total concentrations of mRNAs in tis-
sues collected during the secretory phase three patterns were
detected: a significant increase, a significant decrease and no change.
Specifically, treatment with UPA resulted in a significant decrease in
mRNAs encoded by IGFBP-1 (Fig. 4A), FOXO1 (Fig. 4B), IL15 (Fig. 4C)
and HAND2 (Fig. 4D) compared with secretory phase endometrium.
There was no significant difference in mRNA levels of IGFBP-1, FOXO1,
IL15 and HAND2 between proliferative and UPA-treated endomet-
rium. In contrast, endometrial mRNA concentrations of IHH and
HOXA10 (Fig. 4E and F) were significantly increased between samples
from women treated with UPA and those samples collected in the
secretory phase. There was no significant difference between prolif-
erative phase and UPA-treated endometrium. Concentrations of
FOXM1 mRNA were significantly decreased in both secretory phase
and UPA samples compared with proliferative phase (Fig. 4G). There
was no significant menstrual cycle or UPA-dependent change in
COUP TFII, BMP2 or PTEN although a weak UPA effect was noted
(Fig. 4H–J).
Impact of UPA on immunoexpression
of proteins normally present in the
progesterone-dependent secretory phase
of the cycle
In keeping with the impact of UPA on concentrations of mRNA;
immunolocalisation of FOXO1 was intense in the nuclei of the glandu-
lar epithelium in secretory phase endometrium; immunostaining was
minimal in both proliferative phase and following UPA treatment
(Fig. 5A–D). HAND2 immunolocalisation was most dense in the nuclei
Figure 2 Treatment with SPRM, UPA, increased the concentration of mRNAs encoding sex-steroid receptors in tissue extracts from human endo-
metrium as determined by qRT-PCR. Samples were from women with fibroids obtained during the proliferative and secretory phases or after UPA
administration: n = 9 for each group. PR (A), PRB (B), AR (C), ESR1 (D). *P < 0.05, **P < 0.01, ***P < 0.001. Bars: mean ± SEM.
6 Whitaker et al.
of stromal fibroblasts of secretory phase endometrium with less
intense staining in proliferative and UPA-treated endometrium
(Fig. 5E–H). HOXA10 immunolocalisation was present in stromal cells
of both control and UPA-treated samples, with less intense staining
observed in proliferative phase compared with either secretory or
UPA-treated samples (Fig. 5I–L). PTEN immunolocalisation paralleled
that of mRNA concentrations with minimal alteration between groups
(Fig. 5M–P).
Figure 3 Administration of SPRM, UPA, modulates sex-steroid receptor localization. Representative immuno-localization of progesterone receptor
(PR; A–D), PRB (E–H), androgen receptor (AR; I–L) and estrogen receptor alpha (ERα;M–P) in endometrium from woman with fibroids during pro-
liferative and secretory stages and after UPA administration. Subject A shows endometrium in which PAEC are characterized by extensive cystic glan-
dular dilatation; Subject I has PAEC with minimal cystic change. Neither subject had evidence of submucosal fibroids, and both women described
amenorrhoea on UPA treatment. Samples from UPA-treated women displayed intense immunopositive (+ = positive and − = negative) glandular
nuclei with only a few immunopositive cells in the stroma, a result in contrast with proliferative phase (G+S+) or secretory phase (G−S+). ×40 magni-
fication (scale bar = 50 µm); G, Glands; S, Stroma. Negative controls shown as inserts on secretory endometrium.
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Figure 4 Selective progesterone (P) receptor modulator, UPA, administration impacts on concentrations of P-responsive genes. Relative quantifica-
tion of P-responsive genes in tissue extracts from human endometrium as determined by qRT-PCR. Samples were from women with fibroids obtained
during the proliferative and secretory phases or after UPA treatment: n = 9 for each group. IGFBP-1 (A), FOXO1 (B), IL-15 (C), HAND2 (D),
IHH (E), HOXA-10 (F), FOXM1 (G), COUP TF11 (H), BMP2 (I), PTEN (J). *P < 0.05, **P < 0.01, ***P < 0.001. Bars: mean ± SEM.
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UPA administration does not increase
endometrial cell proliferation
Immunoexpression of Ki67 was used to assess cell proliferation within
the stromal and glandular compartments of the endometrium. As
expected immunopositive staining for Ki67 was detected in nuclei of
both stromal cells and glandular epithelium in endometrium during
proliferative phase and appeared more numerous than in secretory
phase tissue (Fig. 6A and B). In glandular cells UPA treatment
appeared to reduce Ki67 immunoexpression compared to samples
from proliferative phase (Fig. 6C or D versus A). Quantification of pro-
liferating cells confirmed that there were significantly more Ki67 posi-
tive cells in proliferative phase tissue compared to both secretory
Figure 5 Effects of SPRM, UPA, administration on mRNA levels are reflected in modulation of protein localization. Representative images showing
immuno-localization of FOXO1 (A–D), HAND2 (E–H), HOXA10 (I–L) and PTEN (M–P) in endometrium from woman with fibroids at proliferative
and secretory stages and after UPA treatment. Subject A shows endometrium in which PAEC are characterized by extensive cystic glandular dilatation;
Subject I has PAEC with minimal cystic glandular change. ×40 magnification (scale bar = 50 µm); G: Glands, S: Stroma. Negative controls shown as
inserts on secretory endometrium.
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phase and UPA-treated endometrium (Fig. 6E). Analysis of stromal
cells showed a significant reduction in Ki67 positive cells in secretory
phase and in UPA-treated samples. In glandular epithelium Ki67 posi-
tive cells were significantly decreased in secretory compared to prolif-
erative phase: UPA-treated tissue showed a similar trend although this
did not reach significance (P = 0.069) (Fig. 6E–G).
Discussion
UPA is a SPRM which, like other members of this class of compound,
exhibits both agonist and antagonist activities in vitro (Wagenfeld et al.,
2016). The impact of SPRMs is tissue-dependent and may be influ-
enced both by bioavailabilty of different PR isoforms and the concen-
trations of different co-repressor and co-activator proteins in different
cell types (Wagenfeld et al., 2016). In this study, we have demon-
strated that UPA administration alters the pattern of expression of
both PR and AR and mimics the anti-proliferative impact of progester-
one in secretory phase endometrium.
We have conducted a comprehensive analysis of the pattern of gene
expression in endometrium from women with fibroids treated with
UPA prior to hysterectomy and compared this to untreated endomet-
rium from women who also had fibroids. In keeping with the estab-
lished literature (Williams et al., 2012) the extent of morphological
change within the endometrium varied. Larger studies have demonstrated
PAEC rates of around 60% following short but repeated courses of
UPA administration although there is an evidence demonstrating that
PAEC rapidly regresses on cessation of treatment (Donnez et al.,
2014). Why not all subjects develop PAEC is uncertain and the impact
of this morphological observation upon symptom control is unknown;
in our study the degree of PAEC was not correlated with duration of
treatment.
Two isoforms of PR are expressed in a differential manner within
the endometrium (Mote et al., 1999). Our data herein demonstrate
downregulation of both PR isoforms within the stroma and upregula-
tion within the glandular epithelium following UPA administration. This
finding is consistent with previous reports studying the effect of the
SPRM asoprisnil on PR protein localization in human endometrium
(Wilkens et al., 2013). The pattern of expression of ESR1 (ERα)
mRNA and protein after treatment with UPA was similar to that of
the proliferative phase showing this SPRM did not induce PR-
dependent downregulation of ERα gene expression. This finding is
similar to findings for the PR-antagonist mifepristone when adminis-
tered to Rhesus macaques (Slayden and Brenner, 1994).
One of the most striking and consistent findings in this study using
the SPRM UPA was a significant increase in concentrations of AR
mRNA, which was accompanied by a unique pattern of AR protein
expression, distinct to that reported during the normal menstrual cycle
(Marshall et al., 2011). These findings in human are consistent with
Figure 6 SPRM, UPA, administration does not increase endometrial cell proliferation. Proliferation assessed by Ki67 immunohistochemistry (A–D)
and stereological quantification (E–G). Subject A shows endometrium in which PAEC are characterized by extensive cystic glandular dilatation; Subject I has
PAEC with minimal cystic change. ×40 magnification (scale bar = 50 µm); G: Glands, S: Stroma. Kruskal–Wallis statistical test *P < 0.05; **P < 0.01.
10 Whitaker et al.
reports from analysis of endometrium from Rhesus macaques follow-
ing treatment with an intrauterine device containing UPA for three
artificial menstrual cycles (Brenner et al., 2010). A similar effect has
been reported following treatment with mifepristone, which increased
stromal and glandular AR immunoexpression in Rhesus macaques
(Slayden et al., 2001) and in women treated with a single post-
ovulatory dose of the SPRM (Slayden et al., 2001).
To explore whether UPA was acting as an agonist or antagonist with
respect to progesterone-dependent gene expression we measured
mRNAs encoded by genes that have been identified in rodent studies
where PR and PRB have been conditionally knocked-out or increased
during the progesterone-dominated secretory phase of the cycle
(Wetendorf and DeMayo, 2012). Consistent with previous reports,
mRNAs encoded by IGFBP-1, FOXO1, IL-15 and HAND2 were all sig-
nificantly increased in secretory phase control samples compared with
those in proliferative phase. Treatment with UPA resulted in mRNA
concentrations similar to proliferative phase and significantly lower
than secretory phase, consistent with lack of morphological differenti-
ation and suggesting UPA exhibiting limited PR-dependent agonism in
endometrium. Previous work using human endometrial stromal cells
treated with a decidualisation stimulus has suggested that HAND2 may
regulate FOXO1 and IGFBP-1 expression (Huyen and Bany, 2011) and
thus the reduction in HAND2 by UPA may be implicated in the reduc-
tion of FOXO1 and IGFBP-1. Other studies have shown expression of
FOXO1 in endometrial stromal cells is upregulated by cAMP and pro-
gesterone (Labied et al., 2006) and a genomic screen of human endo-
metrial stromal cells treated with a decidualisation protocol showed
15% of the genes induced were aberrantly expressed if FOXO1 was
knocked down with key targets including IGFBP-1 (Vasquez et al.,
2015). As FOXO1 binding sites are present in the majority of DNA
regions associated with PR binding (Vasquez et al., 2015) our finding of
reduced expression of FOXO1 in UPA-treated women may explain
some of the changes in PR-dependent genes.
In the normal menstrual cycle IL-15 rises in response to progester-
one (Dunn et al., 2002). Suppression of genes in the IL-15 pathway
have been reported following asoprisnil administration. This observa-
tion was corroborated with reduced expression of IL-15 mRNA and
the absence of endometrial CD-56 positive cells on immunolocalisa-
tion (Wilkens et al., 2013). In our current data set, IL-15 expression in
UPA-treated endometrium was reduced compared to secretory
phase endometrium consistent with UPA lacking agonist activity;
however, the impact upon the CD-56 positive immune-cell popula-
tion was not investigated.
IHH has been identified as a rapidly induced mediator of PR activa-
tion that localizes to the luminal and glandular epithelium (Takamoto
et al., 2002) and acts in a paracrine fashion to initiate a cascade of gene
expression in the stromal cell compartment (Takamoto et al., 2002).
Whilst one genome wide molecular phenotyping study indicated that
IHH was downregulated during the progression of the endometrium
through the secretory phase (Talbi et al., 2006), Wei et al. (2010)
reported that IHH protein expression was upregulated in secretory
when compared to proliferative endometrium. The same authors, also
reported an upregulation of IHH mRNA of 12 women in response to
UPA in proliferative endometrium suggesting that UPA administration
may have had an agonistic PR effect. In our study, IHH mRNA was
reduced in secretory phase samples compared with those in the prolif-
erative phase. Treatment with UPA was associated with mRNA
concentrations similar to those in the proliferative phase. There are a
number of reasons that may explain these contrasting findings. The
dose of UPA administered in our study was lower (5 mg daily) com-
pared with 10–20 mg. In our study, all UPA patients exhibited PAEC
to a greater or lesser degree in contrast to low levels of PAEC
reported by Wei et al. It is unknown what impact the development of
endometrial PAEC may have had on our data.
HOXA10 is an important transcription factor for endometrial
development including decidualisation. HOXA10 is expressed in both
glandular and stromal compartments and expression is regulated by
both estradiol and progesterone (Eun Kwon and Taylor, 2004). In
healthy women expression peaks during mid-secretory phase and its
expression is considered an important factor in endometrial receptiv-
ity (Kulp et al., 2016). In women with uterine fibroids secretory phase
upregulation may be impaired (Makker et al., 2016). As all our sub-
jects had fibroids this may explain why we demonstrated a reduced
expression of HOXA10 mRNA from the secretory endometrium
compared with proliferative phase at the PCR level although this was
not reflected in protein expression. In those subjects exposed to
UPA, HOXA10 mRNA expression was similar to proliferative phase.
Evidence regarding HOXA10 gene expression in women with uterine
pathology is beginning to emerge with evidence of alterations in gene
methylation suggesting this may be a common molecular mechanism
that becomes aberrant in some conditions (Kulp et al., 2016). Future
studies may shed light on this by exploring the impact of UPA on
HOXA10 promoter methylation but this was outside the scope of the
current study.
In this study, COUP TFII and BMP2 mRNA levels were constant irre-
spective of stage of cycle or PR modulation or UPA treatment. PTEN
acts as a tumour suppressor. Inactivation of this is a common feature
of endometrial cancer, particularly endometrioid subtypes, and often
predates morphological evidence of malignancy and pre-malignant
precursors. Exogenous progestins may play an important role in elim-
ination of PTEN-null glands (Orbo et al., 2006). Here we have shown
that administration of UPA had little effect on PTEN, consistent with
observations after asoprisnil administration (Wilkens et al., 2009).
In women treated with UPA circulating estrogen levels are main-
tained and it is therefore important to determine whether rates of
endometrial cell proliferation increase with treatment. The Ki67 anti-
gen is expressed during several phases of the cell cycle (G1, S, G2 and
M), and is a well established prognostic and predictive biomarker and
cell proliferation marker in clinical assessment of endometrium
(Sivalingam et al., 2016). We thus considered Ki67 a reasonable
choice for assessment of cell proliferation in endometrium in the pre-
sent study.
In the current study, there was no evidence that rates of cell prolif-
eration were increased compared with secretory phase and the num-
ber of ki67 immunopositive cells in both stromal and epithelial
compartments was significantly lower than in proliferative phase. This
is consistent with effects observed with other SPRMs (Wilkens et al.,
2009) but such data have not previously been demonstrated in a quan-
titative manner following UPA administration. The mechanisms
responsible for the low level of proliferation in UPA-treated women
have not been explored. AR regulation has been implicated in the
endometrial anti-proliferative effect observed with mifepristone
administration (Slayden and Brenner, 1994). It is notable that AR
is present in both stromal and epithelial cell nuclei and androgens
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are known to have anti-proliferative effects on endometrial tissue
(Miller et al., 1986). In primates co-administration of mifepristone with
the anti-androgen flutamide abolished the reduction in mitotic indices
and endometrial atrophy (Brenner et al., 2003). The overexpression of
AR in epithelial cells may be implicated in the low epithelial cell prolif-
eration after UPA treatment. The impact of androgens on develop-
ment of endometrial malignancy is complex (Gibson et al., 2014) and
further studies on the relationship between UPA and AR are merited.
UPA-dependent changes in expression of other factors may also play a
role in the low levels of cell proliferation. For example, mRNAs
encoded by FOXM1, a transcription factor that plays crucial roles in
cell proliferation (Gao et al., 2015), were highest in the proliferative
phase samples consistent with previous reports. FOXM1 was reduced
in both secretory phase and UPA-treated samples and whether the
low level of this transcription factor contributes to reduced cell prolif-
eration merits further investigation.
Conclusions
Newmedical therapies for HMB are required and UPA has shown prom-
ise as a treatment for fibroids but its direct impacts on endometrium
have received less attention. In this study, we have focused on an in-
depth analysis of a cohort of women treated with UPA for 9–12 weeks
prior to hysterectomy. The treatment resulted in changes in endometrial
morphology and gene expression consistent with UPA acting as a PR
antagonist in the absence of an increased rate of endometrial cell prolifer-
ation. These novel data indicate that UPA has the potential to fill an
unmet clinical need in treatment of HMB.
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